Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lai, Peibao
NCT06142318: Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma	Recruiting	2	66	RoW	Pirfenidone, Placebo	Nanfang Hospital, Southern Medical University	Head and Neck Squamous Cell Carcinoma, Radiotherapy, Radiosensitizer, Pirfenidone	01/25	06/25
NCT06307314: Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis	Recruiting	N/A	300	RoW		Nanfang Hospital, Southern Medical University	Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker	12/26	12/26
NFEC-2024-067, NCT06276088: Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy	Recruiting	N/A	374	RoW		Nanfang Hospital, Southern Medical University	Immunotherapy, Hyperprogression, Biomarker	12/25	10/26
NCT06307327: Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis	Recruiting	N/A	894	RoW		Nanfang Hospital, Southern Medical University	Head and Neck Cancer, Radiation-Induced Mucositis	12/25	12/26
Sun, Jianda
NCT06142318: Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma	Recruiting	2	66	RoW	Pirfenidone, Placebo	Nanfang Hospital, Southern Medical University	Head and Neck Squamous Cell Carcinoma, Radiotherapy, Radiosensitizer, Pirfenidone	01/25	06/25
NCT06307314: Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis	Recruiting	N/A	300	RoW		Nanfang Hospital, Southern Medical University	Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker	12/26	12/26
NFEC-2024-067, NCT06276088: Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy	Recruiting	N/A	374	RoW		Nanfang Hospital, Southern Medical University	Immunotherapy, Hyperprogression, Biomarker	12/25	10/26
NCT06307327: Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis	Recruiting	N/A	894	RoW		Nanfang Hospital, Southern Medical University	Head and Neck Cancer, Radiation-Induced Mucositis	12/25	12/26